Amphastar Pharmaceuticals (AMPH) Operating Expenses (2013 - 2026)

Amphastar Pharmaceuticals has reported Operating Expenses for 14 years, with the latest figure at $53.7 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 21.3% year-over-year to $53.7 million in Q2 2026; TTM through Jun 2026 was $239.2 million, a 32.19% increase from a year earlier, with the FY2025 full-year figure at $215.7 million, up 28.03% from the prior year.
• Operating Expenses was $53.7 million for Q2 2026 at Amphastar Pharmaceuticals, down from $56.7 million in the prior quarter.
• The five-year high for Operating Expenses was $78.7 million in Q3 2025, with the low at $33.3 million in Q4 2022.
• Average Operating Expenses over 5 years is $44.4 million, with a median of $41.8 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses fell 6.98% in 2023, then jumped 66.79% in 2025.
• Over 5 years, Operating Expenses stood at $33.3 million in 2022, then increased by 26.47% to $42.2 million in 2023, then retreated by 1.56% to $41.5 million in 2024, then gained by 20.62% to $50.1 million in 2025, then grew by 7.34% to $53.7 million in 2026.
• The last three Operating Expenses figures came in at $53.7 million (Q2 2026), $56.7 million (Q1 2026), and $50.1 million (Q4 2025), per Business Quant data.